Components
Community claim
Additional appetite or weight effect.
Community and market provenance
Community mention, not clinical evidence
- Source: pdf08 · Page 1
Evidence of the exact combination
No controlled clinical validation of this exact marketed combination was established in this review. Ingredient evidence is not combination evidence.
Component links are not combination evidence. A commercial name’s composition may vary.
Uncertainty and risks
Overlapping metabolic effects and gastrointestinal intolerance are plausible concerns. The combination cannot inherit results from CagriSema; supplier codes alone may be ambiguous.
Observed in supplier/community material; prevalence not quantified.
No dosing or mixing instructions are provided.
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PMID37366315
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML, Retatrutide Phase 2 Obesity Trial Investigators.
October 16, 2026
- PMID40544433
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
Garvey WT, Blüher M, Osorto Contreras CK, Davies MJ, Winning Lehmann E, Pietiläinen KH, Rubino D, Sbraccia P, Wadden T, Zeuthen N, Wilding JPH, REDEFINE 1 Study Group.
October 16, 2026
- PMID42810372
Bellido V, le Roux CW, Ekinci EI, Bjornstad P, Frias JP, Giblin K, Eyde S, Park SY, Ferro J, Johnson C, Taylor A.
October 16, 2026
- R28
- R29
- R30
- SEARCH-PUBMED-cagrilintide
PubMed/MED targeted search: TITLE:"cagrilintide" AND TITLE:phase
October 16, 2026